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Key points 37 
Question  Which genetic loci associate with keratoconus? 38 
Findings  In this case-control genome-wide association study, with three independent replication cohorts, a 39 
locus containing multiple variants across six protein-coding genes on chromosome 11 was associated with 40 
keratoconus. Several of these genes are likely involved in apoptotic pathways. 41 
Meaning  This study of patients with keratoconus demonstrates a potential role of genes involved in 42 
apoptotic pathways. 43 





Importance  Keratoconus is a condition in which the cornea progressively thins and protrudes in a conical 46 
shape, severely affecting refraction and vision. It is a major indication for corneal transplantation. To 47 
discover new genetic loci associated with keratoconus and to better understand the causative mechanism of 48 
this disease, we performed a genome-wide association study (GWAS) on patients with keratoconus. 49 
Objective  To identify keratoconus genetic susceptibility regions in the human genome. 50 
Design  The discovery cohort was genotyped using the Illumina HumanCoreExome single nucleotide 51 
polymorphism (SNP) array. Following quality control and data cleaning, genotypes were imputed against the 52 
1000 Genomes Project reference panel (Phase III, version 5) and association analysis was completed using 53 
PLINK. SNPs with P < 1 × 10−6 were assessed for replication in three additional cohorts. 54 
Setting  Eye clinics in Australia, the USA, and Northern Ireland. 55 
Participants  The discovery cohort comprised 522 Australian keratoconus cases and 655 Australian 56 
controls. Controls were drawn from the Blue Mountains Eye Study and normal individuals previously 57 
recruited as controls for a study of glaucoma. Replication cohorts were a previous keratoconus GWAS 58 
dataset from the USA (222 cases, 2927 controls); 331 cases and 229 controls from Australia and Northern 59 
Ireland (AUS+NI), and an Australian case–control cohort (VIC, 265 cases, 702 controls). 60 
Main Outcomes and Measures  Associations between keratoconus and 6,252,612 genetic variants were 61 
estimated using logistic regression, were adjusting for ancestry using the first three principal components. 62 
Results  Two novel loci reached genome-wide significance (defined as P < 5 × 10−8), with P = 7.46 × 10−9 at 63 
rs61876744 in PNPLA2 on chromosome 11 and P = 6.35 × 10−12 at rs138380 2.2kb upstream of CSNK1E on 64 
chromosome 22. One additional locus was identified with P < 10−6, in MAML2 on chromosome 11. The 65 
novel locus in PNPLA2 reached genome-wide significance in meta-analysis of all four cohorts (P = 2.45 × 66 
10−8). 67 
Conclusions and Relevance  In this relatively large keratoconus GWAS, we identified a genome-wide 68 
significant locus for keratoconus in the region of PNPLA2 on chromosome 11. 69 





Keratoconus is characterized by progressive thinning of the cornea, the clear tissue at the front of the eye. 72 
Asymmetrical bulging and conical protrusion of the cornea leads to extreme refractive error (myopia and 73 
irregular astigmatism) causing severe visual impairment.1 Keratoconus is relatively common, with a reported 74 
prevalence of around 55 per 100,000 in white populations1 and up to 229 per 100,000 in Asian populations.2 75 
Due to recent advances in diagnostic imaging the true incidence and prevalence of keratoconus may be 5 to 76 
10 times higher than previously reported.3 The etiology of keratoconus is poorly understood. Links have 77 
been made to eye rubbing and atopy, but no direct causative connection has been established.4 Various 78 
biochemical pathways may be involved, including oxidative stress, apoptosis, and disruption to extracellular 79 
matrix turnover.5 80 
Although many cases of keratoconus present as sporadic, there is a well-recognised genetic component to the 81 
disease. The estimated prevalence in relatives of keratoconus patients is 3.34% (95% CI: 3.22–3.46%), 82 
which is 15–67 times higher than in the general population.6 In addition, more than 20 syndromes are 83 
associated with keratoconus, including Down syndrome, Leber congenital amaurosis, and several connective 84 
tissue disorders.7 Linkage studies have identified at least 16 loci for keratoconus;8,9 however, the causative 85 
genes and variants have remained elusive. Common variants in the DOCK910 and LOX11 genes have been 86 
implicated as well as rare mutations in MIR184,12,13 although these loci have not been broadly replicated. 87 
Genome-wide association studies (GWAS) have implicated several loci. Variation in the promoter region of 88 
the HGF gene14,15 and upstream of RAB3GAP116,17 have both been associated in multiple independent 89 
studies. Further, a GWAS for central corneal thickness (CCT) identified loci that are also associated with 90 
keratoconus, including RXRA–COL5A1, FOXO1 and FNDC3B,18 and more recently a suggestive association 91 
at DCN.19 92 
We present findings from a GWAS of 522 patients with keratoconus, a relatively large sample for this 93 






Study design 97 
We report a study of 4 independent Caucasian cohorts of patients with keratoconus. The first case–control 98 
cohort used for the discovery phase comprised 522 keratoconus patients and 655 controls. All single 99 
nucleotide polymorphisms (SNPs) with P < 1 × 10−6 were looked up in imputed genotypes from a previously 100 
published GWAS study of 222 keratoconus patients and 3324 controls from the USA. In addition, 27 SNPs 101 
were genotyped in an independent replication cohort of 331 cases and 229 controls from Australia and 102 
Northern Ireland (AUS+NI), and in an additional 265 cases and 702 controls from Victoria, Australia (VIC). 103 
The demographics for each cohort are given in Table 1. 104 
Discovery cohort 105 
The protocol was approved by the Southern Adelaide Clinical Human Research Ethics Committee (HREC) 106 
and the HREC of the Royal Victorian Eye and Ear Hospital and the Health and Medical HREC of the 107 
University of Tasmania. All participants gave written informed consent and the study conformed to the 108 
tenets of the Declaration of Helsinki. Participants with keratoconus were ascertained through the eye clinic 109 
of Flinders Medical Centre, Adelaide; optometry and ophthalmology clinics in Adelaide and Melbourne; or 110 
an Australia-wide invitation to members of Keratoconus Australia, a community-based support group for 111 
patients. Clinical data were obtained from the participants’ eye care practitioner. 112 
The diagnosis of keratoconus was based on both clinical examination and videokeratography pattern analysis 113 
as described previously.20 Clinical examination included slit-lamp biomicroscopy, cycloplegic retinoscopy, 114 
and fundus evaluation. Slit-lamp biomicroscopy was used to identify stromal corneal thinning, Vogts’ striae, 115 
or a Fleischer ring. Retinoscopy examination was performed on a fully dilated pupil to determine the 116 
presence or absence of retro-illumination signs of keratoconus, such as the oil droplet sign and scissoring of 117 
the red reflex. Videokeratography evaluation was performed on each eye using the Orbscan (Orbtek/Bausch 118 
& Lomb, Salt Lake City, UT, USA). Patients were classified as having keratoconus if they had at least one 119 
clinical sign of keratoconus and a confirmatory videokeratography.21 A history of penetrating keratoplasty 120 




of keratoconus were excluded, and if multiple individuals from the same family presented, only one was 122 
included. 123 
Controls were obtained from the Australian cohort previously described in a GWAS for age-related macular 124 
degeneration (AMD) from the International AMD Genomics Consortium22 and have been described in detail 125 
previously. For the current analysis, data from 676 Australian unaffected controls (including 465 from the 126 
Blue Mountains Eye Study23 and 211 normal individuals previously recruited as controls for a study of 127 
glaucoma24) were combined as controls for keratoconus. Related individuals and those who did not pass all 128 
sample QC for the AMD GWAS were excluded. 129 
DNA for cases and controls was extracted from whole blood using the QiaAMP DNA Maxi kit (Qiagen, 130 
Hilden, Germany). 131 
Genotyping and data quality control 132 
Cases were genotyped for 551,839 variants using the HumanCoreExome array (HumanCoreExome-24v1-133 
1_A, Illumina, San Diego, CA, USA). For the controls, genotypes of 569,645 variants were generated with a 134 
customized Illumina HumanCoreExome array (“HumanCoreExome_Goncalo_15038949_A”) as described 135 
previously.22 136 
Quality control was carried out according to the protocol described by Anderson et al25, modified as follows. 137 
Reverse and ambiguous strand SNPs were detected using snpflip (https://github.com/biocore-ntnu/snpflip, 138 
accessed March 24, 2017) and flipped or excluded. Only SNPs common to both arrays were included. 139 
Individuals with discordant sex information, missing genotype rate >0.05, or heterozygosity more than 3 140 
standard deviations from the mean were excluded. Related individuals were detected by calculating pairwise 141 
identity by descent (IBD), and the individual with the lower genotyping rate in any pair with IBD >0.185 142 
was removed. Ancestry outliers were identified by principal component analysis (PCA) using 143 
EIGENSTRAT,26 and removed. Markers were excluded if they had missing genotype rate >3%, significantly 144 
different missing data rates between cases and controls, minor allele frequency (MAF) <0.01, or deviated 145 
significantly (P < 10−5) from Hardy–Weinberg equilibrium. Following all exclusions, there were 522 cases 146 




Genomic imputation and association analysis 148 
We phased autosomal genotype data using Eagle (version 2.3.5)27 and then imputed genotypes on the basis 149 
of the EUR subset of the 1000 Genomes Project reference panel (Phase III, version 5)28 using Minimac3 150 
(version 2.0.1).29 We excluded indels, SNPs within 5bp of an indel, rare variants (MAF <0.01), and variants 151 
with poor imputation quality (R2 < 0.8). This filtering yielded a total of 6,252,612 quality-controlled variants, 152 
including 250,964 genotyped variants. Association analysis was performed on most-likely genotypes under a 153 
logistic regression model using PLINK (version 1.90)30 using the first three principal components as 154 
covariates. A P value less than 5 × 10−8 was considered significant. 155 
Replication and meta-analysis 156 
The USA cohort has been previously described.18 Briefly, clinically affected Caucasian keratoconus cases (n 157 
= 240) were enrolled into the GWAS31 as a part of the longitudinal videokeratography and genetic study at 158 
the Cornea Genetic Eye Institute.6 After removing samples with poor genotyping quality, 222 samples were 159 
included in the analysis. Caucasian controls (n = 3324) were obtained from the Cardiovascular Health Study 160 
(CHS), a population-based cohort study of risk factors for cardiovascular disease and stroke in adults 65 161 
years of age or older, recruited at 4 field centres.32,33 CHS was approved by the Institutional Review Board at 162 
each recruitment site, and subjects provided informed consent for the use of their genetic information. 163 
African-American CHS participants were excluded from analysis due to insufficient number of ethnically-164 
matched cases. Participants did not have an eye examination to exclude keratoconus. The samples included 165 
in the analysis were from self-reported Caucasians. Outliers detected by PCA were excluded, and the 166 
analysis was adjusted for the top 3 principal components. 167 
IMPUTE version 2.3.0 was used to perform imputation of the genotyping data from 370K BeadChip arrays 168 
(Illumina) in keratoconus patients and CHS Caucasian controls using 1000 Genomes Phase I data as the 169 
reference panel. All SNPs with P < 10−6 identified in the discovery analysis were looked up and extracted, 170 
with the exception of 4 SNPs at the CSNK1E locus that were not imputed in the USA study. 171 
SNPs with P < 10−6 in the discovery cohort were selected for genotyping in additional replication cohorts 172 
using the MassARRAY® System (Agena Bioscience, San Diego, CA, USA) by the Australian Genome 173 




preference given to SNPs with the smallest P value in the discovery cohort. Twenty-seven SNPs were 175 
genotyped in 186 additional cases recruited under the same protocol as the discovery cohort as well as in 145 176 
patients from Northern Ireland, described previously,
14
 for a total of 331 cases. Cases were compared to 229 177 
unaffected examined controls, consisting of 84 individuals from the Blue Mountains Eye Study not included 178 
in the discovery cohort and 145 older individuals recruited from nursing homes in the Launceston area of 179 
Tasmania, Australia. All controls underwent a thorough ocular examination and keratoconus was excluded. 180 
These SNPs were also genotyped in a replication cohort from Melbourne, Victoria, consisting of 265 cases 181 
and 702 examined controls described previously.15 182 
Association was assessed in each cohort individually using logistic regression. Meta-analysis of results from 183 
discovery and replication cohorts was performed using METAL.34 184 
Functional annotation of associated variants 185 
The lead SNP at the novel locus on chromosome 11, rs61876744, was queried in HaploReg V4.1 186 
(https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php; accessed 28 May 2019),35 including data 187 
from the Genotype–Tissue Expression (GTex) pilot analysis.36 Genes in the associated region were assessed 188 
for ocular tissue expression using the Ocular Tissue Database (https://genome.uiowa.edu/otdb/)37 and for 189 




Genome-wide association testing of the discovery cohort 194 
Genome-wide association analysis was conducted in the discovery cohort (Figure 1, eFigure 1 in the 195 
Supplement). The genomic inflation factor was λ1000 = 1.023 and all included samples were of European 196 
ancestry (eFigure 2 in the Supplement). Two novel loci reached genome-wide significance (defined as P < 5 197 
× 10−8), with P = 7.46 × 10−9 at rs61876744 in the PNPLA2 gene on chromosome 11 and P = 6.35 × 10−12 at 198 
rs138380 2.2kb upstream of the CSNK1E gene on chromosome 22. One additional locus was identified with 199 




SNPs with P < 10−6 are shown in eTable 1 in the Supplement. Locus-specific plots for all 3 loci are shown in 201 
eFigure 3 in the Supplement. 202 
The locus on chromosome 11 showing genome-wide significance included 25 SNPs with P < 10−6 spanning 203 
6 protein-coding genes (CEND1, SLC25A22, PANO1, PIDD1, RPLP2 and PNPLA2) and multiple RNA 204 
genes. 205 
Because previously-reported keratoconus risk loci were initially identified in GWAS for CCT, we assessed 206 
each of the loci reaching suggestive significance in the current analysis in our previously reported meta-207 
analysis for CCT. As shown in Table 2, only the MAML2 locus shows nominal association with CCT. We 208 
also looked up the lead SNPs from our CCT meta-analysis in the results from our discovery cohort (eTable 2 209 
in the Supplement). SNPs at FNDC3B, MPDZ, and SMAD3 show nominal association in our analysis. 210 
Association testing of the replication cohorts 211 
All SNPs with P < 10−6 identified in the discovery cohort were analysed in the previously generated GWAS 212 
data for the USA cohort, and 27 SNPs compatible with a single assay design were genotyped in the AUS+NI 213 
and VIC replication cohorts. (Table 3 and eTable 3 in the Supplement). 214 
Multiple SNPs in both novel loci at PNPLA2 and MAML2 showed association with p < 0.05 in the USA 215 
cohort. None of the SNPs in the CSNK1E locus reached significance, although all showed the same direction 216 
of association as in the discovery cohort. None of the 3 loci reached significance in either the AUS+NI or the 217 
VIC replication cohort, but most SNPs showed the same direction of association as the discovery cohort. 218 
MAFs for cases and controls in each cohort are given in eTable 3 in the Supplement. 219 
Meta-analysis 220 
Meta-analysis of the combined data from the discovery and all 3 replication cohorts found 12 SNPs at the 221 
novel PNPLA2 locus to be associated with keratoconus at genome-wide significance (P < 5 × 10−8). The 222 
MAML2 locus on chromosome 11 showed suggestive association with P = 3.83 × 10−6 at rs10831500. The 223 
CSNK1E locus on chromosome 22 reached P = 3.18 × 10−4 at rs138378. For all 3 loci, there were other SNPs 224 
with smaller P values on meta-analysis, but these did not include data for all replication cohorts (eTable 3 in 225 




Functional annotations of novel associated loci 227 
At the significant locus on chromosome 11, the lead SNP rs61876744 is located in the second intron of the 228 
PNPLA2 gene (NM_020376.3). The associated region extends for around 40kbp encompassing multiple 229 
transcripts. The PNPLA2 gene is highly expressed in all eye tissues assessed in the ocular tissue database, 230 
including cornea, as are other protein-coding genes at this locus (eTable 4 in the Supplement). A recent study 231 
compared gene expression in corneal epithelium from keratoconus and myopia patients,38 and found that 232 
PNPLA2 and PIDD1 were differentially expressed with a false discovery rate (FDR) < 0.05 (eTable 4 in the 233 
Supplement) while RPLP2 and CSNK1E are significant at FDR < 0.1. 234 
HaploReg identified 7 SNPs in strong linkage disequilibrium with the lead SNP (rs61876744), and all report 235 
an eQTL for an antisense RNA transcript AP006621 (multiple transcripts 1–8) in multiple tissues assessed in 236 
GTex (eTable 5 in the Supplement) where the more common allele, C, is associated with increased transcript 237 
levels (eFigure 4 in the Supplement). This RNA gene is not represented in the ocular tissue database. A 238 
similar trend is seen in GTex for the PIDD1 gene in sun exposed skin (eFigure 4 in the Supplement). 239 
Discussion 240 
This study has identified a candidate locus for keratoconus on chromosome 11 that shows replication in the 241 
USA data and consistent direction of association in the other cohorts. The lead SNP is located in an intron of 242 
PNPLA2. This gene encodes Patatin-like phospholipase domain-containing protein 2, which catalyzes the 243 
initial step in triglyceride hydrolysis. The relevance of this pathway to keratoconus is not obvious, but it is 244 
well known that the closest gene to an association signal is not necessarily the causative gene. At least 4 245 
other protein coding genes at this locus are also expressed in the cornea, and RNA coding genes are also 246 
annotated in the region. There is a strong eQTL signal of the lead SNP rs61876744 for an antisense RNA 247 
gene, AP006621.8 located on the opposite strand to the protein coding PNPLA2 gene. The antisense RNA 248 
AP006621 transcripts may have a role in regulating PNPLA2 or other genes at this locus and elsewhere. The 249 
minor allele at rs61876744, T, is associated with reduced risk of keratoconus and with reduced expression of 250 
AP006621 in many tissues. This suggests that overexpression of AP006621 may destabilise corneal 251 
structures. Oxidative stress and apoptosis have been suggested as part of the pathogenesis of keratoconus5 252 




genes at this locus likely play a role in apoptotic pathways, including PPID (p53-induced death domain 254 
protein 1) and PANO1 (proapoptotic nucleolar protein 1). 255 
The chromosome 11 locus overlaps with a previously reported (although not genome-wide significant) 256 
association signal for Fuchs Endothelial Corneal Dystrophy (FECD).40 The lead SNP in the FECD GWAS is 257 
rs12223324 in the PDDC1 gene, upstream of PNPLA2. This SNP does not reach significance in our 258 
keratoconus GWAS, (P = 2.02 × 10−5). It is not known how this locus might lead to FECD, but the overlap 259 
of genetic association with keratoconus is intriguing, given both diseases affect the cornea. Although rare, 260 
there are reports in the literature of patients with both FECD and keratoconus.41,42 The participants in the 261 
current study do not have FECD and thus this disease does not account for the association observed here. 262 
Although we observed the strongest association in the discovery cohort at the CSNK1E locus, this result was 263 
not replicated. The signal appears to be driven by a single genotyped SNP that has influenced the imputation 264 
of a surrounding LD block (see eTable 1; eFigure 3C in the Supplement). The signal at the MAML2 locus is 265 
supported by the USA replication cohort. Further replication of these loci is required before any firm 266 
conclusions can be drawn.  267 
All control cohorts used in this study were older than the case cohorts, thus it will be important to assess 268 
these loci for age-related effects in future studies. Batch effects are a potential problem in an analysis where 269 
cases and controls are genotyped separately; however, the low inflation factor seen in our analysis reassures 270 
us that batch effects are unlikely to be having a major impact. 271 
Previous GWAS for keratoconus (using a subset of cases involved in the current study) reported 272 
RAB3GAP131 and a region upstream of the HGF,14 although neither study reached genome-wide 273 
significance. The lead SNPs at these loci reach P values of 0.066 and 0.038 respectively in the current 274 
discovery cohort, suggesting these loci are not major contributors in this better powered study. Previously 275 
reported genome-wide significant keratoconus associated loci (RXRA–COL5A1, FOXO1 and FNDC3B) are 276 
also associated with CCT. The current findings suggest that mechanisms other than susceptibility to a thinner 277 
cornea may also be at play in the genetic risk of keratoconus. 278 
In summary, we have identified a locus for keratoconus on chromosome 11. The lead SNP is in an intron of 279 




MAML2 and CSNK1E that require further replication. It is very likely that additional risk loci exist for 281 
keratoconus, and larger studies will be needed to identify them. 282 
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Figure 1: Manhattan plot of association results in the discovery cohort. Results of logistic 421 
regression with the first three PCs as covariates (−log10 p-values) are plotted for each chromosome. 422 
The red and blue lines represent the genome-wide significance threshold of p = 5 × 10
−8
 and our 423 
threshold for follow-up of p = 10
−6
, respectively. 424 









N % male Mean age [SD] N % male Mean age [SD] 
Discovery: Australia 522 56 45 [15.2] 655 47 65 [10.6] 
Replication: USA 222 55 44 [13.3] 2927 39 72   [5.4] 
Replication: AUS+NI 331 61 41 [15.9] 229 37 75 [11.5] 





Table 2: Lead SNPs at all three loci with p < 1 × 10
−6




 Chr Lead SNP Base pairb A1/2 F_Ac F_Uc ORd [95% CI] P P (CCT)e 
PNPLA2 11 rs61876744 820754 T/C 0.341 0.447 0.59 [0.49–0.71] 7.46 × 10
−9 0.553 
MAML2 11 rs10831500 95982642 G/T 0.422 0.330 1.59 [1.33–1.91] 3.91 × 10
−7 0.014 
CSNK1E 22 rs138380 38796629 G/A 0.384 0.524 0.49 [0.40–0.60] 6.35 × 10
−12 0.790 
 431 
aLocus assigned to the RefSeq protein-coding gene within or near the association signal interval. 432 
bGenomic positions are based on hg19. 433 
cF_A, minor allele frequency in cases; F_U, minor allele frequency in controls. 434 
dOdds ratios with respect to A1. 435 
eP-values in our previously reported analysis for CCT.19 436 




Table 3: Replication and meta-analysis of association results at lead SNPs. 438 
 439 
     Discovery Replication:USA Replication: AUS+NI Replication: VIC Meta-analysis 
Locus
a










P P direction 
PNPLA2 11 rs61876744 820754 T/C 0.59 
[0.49–0.71] 
7.46 × 10−9 0.77 
[0.63–0.95] 




0.763 2.45 × 10−8 −−−− 
MAML2 11 rs10831500 95982642 G/T 1.59 
[1.33–1.91] 
3.91 × 10−7 1.35 
[1.11–1.65] 




0.792 3.83 × 10−6 ++++ 
CSNK1E 22 rs138378 38796159 A/G 0.50 
[0.41–0.61] 






0.448 3.18 × 10−4 −−−− 
 440 
aLocus assigned to the RefSeq protein-coding gene within or near the association signal interval. 441 
bThe lead SNP at CSNK1E (rs138380) was not successfully genotyped in the AUS+NI and VIC cohorts, and a proxy (rs138378, R2=0.938) was used for replication 442 
instead. 443 
cGenomic positions are based on hg19. 444 
 445 

